Merck & Co., Inc: Vaginal Neoplasms trials

The registry lists 10 Vaginal Neoplasms studies with Merck & Co., Inc as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 1 1Phase 2 2Phase 3 6No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)CompletedNCT03546842Phase 3Results posted
• Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)CompletedNCT03158220Phase 3Results posted
• GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)CompletedNCT01245764Phase 3Results posted
• A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)CompletedNCT01047345Phase 3Results posted
• A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)CompletedNCT00943722Phase 3Results posted
• Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)CompletedNCT00851643Phase 1Results posted
• Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)CompletedNCT00543543Phase 3Results posted
• Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)Active, not recruitingNCT02653118
• A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)CompletedNCT00551187Phase 2
• Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)CompletedNCT00520598Phase 2